DF sales are likely to grow 15% YoY to Rs 1,400 crore driven by the integration of the Sanofi portfolio ... 12.5% YoY led by strong growth in Gastro/Derma/Vaccines and in-licensing opportunities.

Sanofi has managed the daunting task faced by managers worldwide: hauling its employees back to the office with minimal fuss. That’s an impressive feat for a company that said last year it was ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.

Sanofi (NASDAQ:SNY) has agreed to acquire an immunology drug from clinical-stage biopharmaceutical company Dren Bio for up to $1.9B. The French pharmaceutical company will acquire DR-0201, a CD20 ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune ...

March 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.

Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

Sanofi is reorganising its business units from seven to five in a bid to streamline its operations and ensure the success of its ambitious product launch plans. The revamp is the first major ...

Sanofi said it would acquire Bispecific Myeloid Cell Engager, an autoimmune disease treatment, from Dren Bio, for up to $1.9 billion. The French pharmaceutical company on Thursday said it would ...

Banks are gearing up to offload the €8.65 billion ($9.5 billion) debt package backing Clayton Dubilier & Rice’s purchase of a stake in Sanofi SA’s consumer health division. Lenders including ...